| 000 | 01578 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250517101349.0 | ||
| 264 | 0 | _c20170524 | |
| 008 | 201705s 0 0 eng d | ||
| 022 | _a1942-5546 | ||
| 024 | 7 |
_a10.1016/j.mayocp.2016.02.023 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNassan, Malik | |
| 245 | 0 | 0 |
_aPharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. _h[electronic resource] |
| 260 |
_bMayo Clinic proceedings _c07 2016 |
||
| 300 |
_a897-907 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 |
_aAntidepressive Agents, Second-Generation _xadverse effects |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2D6 _xgenetics |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aDepressive Disorder, Major _xdrug therapy |
| 650 | 0 | 4 |
_aFluoxetine _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aParoxetine _xadverse effects |
| 650 | 0 | 4 |
_aPharmacogenetics _xmethods |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 |
_aPrecision Medicine _xmethods |
| 650 | 0 | 4 |
_aPrescription Drugs _xstandards |
| 650 | 0 | 4 |
_aVenlafaxine Hydrochloride _xadverse effects |
| 700 | 1 | _aNicholson, Wayne T | |
| 700 | 1 | _aElliott, Michelle A | |
| 700 | 1 | _aRohrer Vitek, Carolyn R | |
| 700 | 1 | _aBlack, John L | |
| 700 | 1 | _aFrye, Mark A | |
| 773 | 0 |
_tMayo Clinic proceedings _gvol. 91 _gno. 7 _gp. 897-907 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.mayocp.2016.02.023 _zAvailable from publisher's website |
| 999 |
_c26115002 _d26115002 |
||